Vor Biopharma Inc. (NASDAQ:VOR) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Vor Biopharma Inc. (NASDAQ:VOR) have been assigned an average recommendation of “Moderate Buy” from the thirteen ratings firms that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, four have given a hold recommendation, six have assigned a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $50.6667.

A number of analysts recently commented on VOR shares. Wells Fargo & Company started coverage on Vor Biopharma in a research report on Thursday, March 19th. They set an “overweight” rating and a $30.00 price objective for the company. Wedbush lifted their price objective on Vor Biopharma to $15.00 and gave the stock a “neutral” rating in a research report on Tuesday, March 31st. Citigroup started coverage on Vor Biopharma in a research report on Friday, January 9th. They set a “buy” rating and a $50.00 price objective for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vor Biopharma in a research report on Wednesday, January 21st. Finally, TD Cowen started coverage on Vor Biopharma in a research report on Wednesday, December 17th. They set a “buy” rating for the company.

Vor Biopharma Price Performance

NASDAQ:VOR opened at $15.47 on Monday. The company has a market capitalization of $755.71 million, a PE ratio of -0.04 and a beta of 1.92. Vor Biopharma has a 52-week low of $2.62 and a 52-week high of $65.80. The stock has a fifty day simple moving average of $14.41 and a 200-day simple moving average of $16.94.

Insider Buying and Selling

In related news, Director Ra Capital Management, L.P. sold 135,201 shares of Vor Biopharma stock in a transaction dated Thursday, April 9th. The stock was sold at an average price of $16.59, for a total transaction of $2,242,984.59. Following the completion of the sale, the director owned 3,936,436 shares in the company, valued at approximately $65,305,473.24. This trade represents a 3.32% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In the last three months, insiders sold 1,469,390 shares of company stock worth $24,749,633. Company insiders own 0.45% of the company’s stock.

Institutional Trading of Vor Biopharma

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. XTX Topco Ltd purchased a new stake in Vor Biopharma during the 4th quarter worth about $229,000. Susquehanna Portfolio Strategies LLC purchased a new stake in Vor Biopharma in the 4th quarter valued at about $134,000. Tudor Investment Corp ET AL purchased a new stake in Vor Biopharma in the 4th quarter valued at about $2,193,000. Sphera Funds Management LTD. purchased a new stake in Vor Biopharma in the 4th quarter valued at about $5,368,000. Finally, Quadrature Capital Ltd purchased a new stake in Vor Biopharma in the 4th quarter valued at about $350,000. Hedge funds and other institutional investors own 97.29% of the company’s stock.

Vor Biopharma Company Profile

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).